ABV-103 Anti-Marburg virus disease Therapeutic

ABV-103 is a humanized macaque-derived monoclonal antibody with potent and broad neutralizing activity toward all strains of Marburg and Ravn viruses. ABV-103 has provided protection against lethal challenge with these viruses in animal models including gold standard nonhuman primates. ABV-103 is currently at the IND-enabling stage under a NIAID funded program.

Relevant publications for IBT-T02:

Zhao X, Howell KA, He S, Brannan JM, Wec AZ, Davidson E, Turner HL, Chiang CI, Lei L, Fels JM, Vu H, Shulenin S, Turonis AN, Kuehne AI, Liu G, Ta M, Wang Y, Sundling C, Xiao Y, Spence JS, Doranz BJ, Holtsberg FW, Ward AB, Chandran K, Dye JM, Qiu X, Li Y, Aman MJ. Immunization-Elicited Broadly Protective Antibody Reveals Ebolavirus Fusion Loop as a Site of Vulnerability. Cell. 2017 May 18;169(5):891-904.e15. doi: 10.1016/j.cell.2017.04.038. PMID: 28525756; PMCID: PMC5803079.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5803079/

Brannan JM, He S, Howell KA, Prugar LI, Zhu W, Vu H, Shulenin S, Kailasan S, Raina H, Wong G, Rahim MN, Banadyga L, Tierney K, Zhao X, Li Y, Holtsberg FW, Dye JM, Qiu X, Aman MJ. Post-exposure immunotherapy for two ebolaviruses and Marburg virus in nonhuman primates. Nat Commun. 2019 Jan 10;10(1):105. doi: 10.1038/s41467-018-08040-w. PMID: 30631063; PMCID: PMC6328579.

https://journals.asm.org/doi/full/10.1128/mBio.01438-20

IBT-T02 Pan-Ebolavirus Therapeutic

IBT-T02 is a cocktail of two monoclonal antibodies with potent neutralizing activity against Ebola, Sudan, and Bundibugyo viruses. IBT-T02 has provided full protection against lethal challenge with these viruses in nonhuman primates, ferrets, guinea pigs, and mice. IBT-T02 is currently at the IND-enabling stage.

Relevant publications for IBT-T02:

ZZhao X, Howell KA, He S, Brannan JM, Wec AZ, Davidson E, Turner HL, Chiang CI, Lei L, Fels JM, Vu H, Shulenin S, Turonis AN, Kuehne AI, Liu G, Ta M, Wang Y, Sundling C, Xiao Y, Spence JS, Doranz BJ, Holtsberg FW, Ward AB, Chandran K, Dye JM, Qiu X, Li Y, Aman MJ. Immunization-Elicited Broadly Protective Antibody Reveals Ebolavirus Fusion Loop as a Site of Vulnerability. Cell. 2017 May 18;169(5):891-904.e15. doi: 10.1016/j.cell.2017.04.038. PMID: 28525756; PMCID: PMC5803079.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5803079/

ABV-103 Anti-Marburg virus disease Therapeutic

ABV-103 is a humanized macaque-derived monoclonal antibody with potent and broad neutralizing activity toward all strains of Marburg and Ravn viruses. ABV-103 has provided protection against lethal challenge with these viruses in animal models including gold standard nonhuman primates. ABV-103 is currently at the IND-enabling stage under a NIAID funded program.

Influenza Monoclonal Antibody

AbVacc in collaboration with Abviro, LLC has developed a pan-influenza A monoclonal antibody with broad heterosubtypic effective treatment for both Group 1 and 2 influenza A viruses regardless of group specificity, without inducing virus resistance.

This project has currently selected a stable CHO clone for antibody production. Antibody purified from this clone will be evaluated in a number of Influenza strains including high path AI (HPAI) followed by studies to support IND submission.

ABV-104: S. aureus monoclonal antibody cocktail

Invasive Staphylococcus aureus (SA) infections are a major driver of morbidity and mortality in hospital settings and in the community. Growing antimicrobial resistance among SA strains make development of non-antibiotic treatments such as immunotherapy as adjunct therapeutics a pressing need. In collaboration with Eliteimmune, Inc., AbVacc has developed a strong portfolio of highly potent antibodies against key toxins, superantigens, and other virulence factors of S. aureus. A cocktail of these antibodies is being evaluated against several life-threatening syndromes of S. aureus infections.

Relevant publications for ABV-104:

https://pubmed.ncbi.nlm.nih.gov/35730685/

Cd-ISTAb - ISTAb against Clostridium difficile infection

ISTAb, neutralizing antibody cocktail against TcdB engineered to target to the surface of C. difficile to achieve both neutralization and bacterial clearance for treatment of CDI.

Cd-ISTAb is an engineered antibody for treatment of C. difficile infections (CDI). The strategy is based on a novel technology that uses Infection Site Targeted neutralizing anti-toxin Antibodies (ISTAb). ISTAbs are directed to the site of infection through specific phage-derived cell wall targeting (CWT) domains that bind specific bacterial species. Cd-ISTAb integrates toxin neutralization and effector functions into a single therapeutic.

ISTAbs unique properties:

• - Accumulate at the site of infection through binding to the bacteria,
• - Capturing and sequester the toxins as they are released, thereby immediately neutralizing their immune suppressive and tissue destructive effects and prevent toxemia.
• - As the Fc receptor binding sites in the ISTAbs remain intact, ISTAbs mediate opsonophagocytic killing, thus providing a means for concurrent toxin neutralization and bacterial clearance.

Cd-ISTAb is a cocktail of two potent antibodies that neutralize C. difficile Toxin A (TcdA and TcdB) and are targeted to the surface of bacteria.

Ba-ISTAB – ISTAb against Bacillus anthracis

ISTAb, an anti-PA neutralizing antibody targeted to the surface of B. anthracis to achieve both neutralization and bacterial clearance for treatment of Inhalation Anthrax

Ba-ISTAb is an engineered antibody for treatment of infections caused by Bacillus anthracis. The strategy is based on novel technology that uses Infection Site Targeted neutralizing anti-toxin Antibodies (ISTAb). ISTAbs are directed to the site of infection through specific phage-derived cell wall targeting (CWT) domains that bind specific bacterial species. Ba-ISTAb integrates toxin neutralization and effector functions into a single therapeutic.

ISTAbs unique properties:

• - Accumulate at the site of infection through binding to the bacteria,
• - Capturing and sequester the toxins as they are released, thereby immediately neutralizing their immune suppressive and tissue destructive effects and prevent toxemia.
• - As the Fc receptor binding sites in the ISTAbs remain intact, ISTAbs mediate opsonophagocytic killing, thus providing a means for concurrent toxin neutralization and bacterial clearance.

Ba-ISTAb is a fusion of a B. anthracis specific CWT with a potent monoclonal antibody that neutralize Anthrax toxin (PA)